Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,027 public trials 2,025 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

NCT05971251

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

View Trial Details

Active, Not Recruiting

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

NCT07199855

Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China

View Trial Details

Active, Not Recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111

Conditions: DNA Virus Infections, Epstein-Barr Virus Infection, Epstein-Barr Virus Infections, +12 more
Locations: Pinnacle Research Group, LLC Anniston, Alabama, United States

Noble Clinical Research Tucson, Arizona, United States

Marvel Clinical Research Huntington Beach, California, United States

Tekton Research Longmont, Colorado, United States

View all 34 locations

View Trial Details

Active, Not Recruiting

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT03147885

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B-cell Lymphoma, +35 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Active, Not Recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT03015896

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
Locations: Emory University Atlanta, Georgia, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

NCT04479267

Conditions: Diffuse Large B-cell Lymphoma, Double Expressor Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations: Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Active, Not Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

NCT05627856

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital Guangzhou, Guangdong, China

View Trial Details

Active, Not Recruiting

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

NCT05944978

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +16 more
Locations: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Active, Not Recruiting

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

NCT04606433

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +12 more
Locations: The Second Hospital of Anhui Medical University Hefei, Anhui, China

Peking University Third Hospital Beijing, Beijing Municipality, China

Chongqing University Cancer Hospital Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality, China

View Trial Details

Active, Not Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

NCT05192486

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Shenzhen Second People's Hospital Shenzhen, Guangdong, China

Affiliated Hospital of Hebei University Baoding, Hebei, China

The First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China

Ruijin Hospital, Shanghai JiaoTong University School of Medicine Shanghai, Shanghai Municipality, China

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions